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The activation of Toll-like receptors (TLRs) in
dendritic cells (DCs) triggers a rapid inflamma-
tory response to pathogens. However, this
response must be tightly regulated because
unrestrained TLR signaling generates a chronic
inflammatory milieu that often leads to autoim-
munity. We have found that the TAM receptor
tyrosine kinases—Tyro3, Axl, andMer—broadly
inhibit both TLR and TLR-induced cytokine-
receptor cascades. Remarkably, TAM inhibition
of inflammation is transduced through an es-
sential stimulator of inflammation—the type I
interferon receptor (IFNAR)—and its associated
transcription factor STAT1. TLR induction of
IFNAR-STAT1 signaling upregulates the TAM
system, which in turn usurps the IFNAR-STAT1
cassette to induce the cytokine and TLR sup-
pressors SOCS1 and SOCS3. These results illu-
minate a self-regulating cycle of inflammation,
in which the obligatory, cytokine-dependent ac-
tivation of TAMsignaling hijacks a proinflamma-
tory pathway to provide an intrinsic feedback
inhibitor of both TLR- and cytokine-driven im-
mune responses.
INTRODUCTION
The innate immune response to pathogens represents the
first line of defense against infectious disease. Among the
most potent mediators of this response are the TLRs, a set
of receptors that activate host defenses responsible for
local inflammation, the recruitment of effector cells, and
the secretion of cytokines that modulate both the innate
and adaptive immune responses (Akira et al., 2006; Beu-
tler et al., 2006). TLRs are ‘‘pattern-recognition receptors’’
that detect invariant molecular signatures displayed by1124 Cell 131, 1124–1136, December 14, 2007 ª2007 Elsevierinvading pathogens. TLR-4, for example, recognizes bac-
terial lipopolysaccharide (LPS), whereas TLR-9 recog-
nizes bacterial DNA that contains unmethylated CpG
dinucleotides, and TLR-3 and TLR-7 are activated by dou-
ble- and single-stranded RNAs, respectively (Akira et al.,
2006; Beutler et al., 2006).
TLRs are prominently expressed in sentinel cells, such
as DCs and macrophages, which drive the innate immune
response (Iwasaki and Medzhitov, 2004). Activation of
these receptors engages multiple intracellular adaptor
and signaling proteins, including MyD88, TRIF, and
TRAF6 (Akira, 2006). Subsequently, evolutionarily ancient
signal transduction cascades, centeredon theMAPkinase
pathways and the NF-kB and interferon response factor
(IRF) transcription factors, are activated, resulting in the in-
duction of proinflammatory cytokines suchas interleukin-6
(IL-6), IL-12, tumor necrosis factor (TNF)-a, and type I inter-
ferons (IFNs). Additionally, DCs are the professional
antigen-presenting cells (APCs) that bridge the innate
and adaptive immune responses. TLR activation in DCs
induces the secretion of cytokines and the upregulation
of costimulatory molecules that subsequently orchestrate
the adaptive response (Iwasaki and Medzhitov, 2004).
Although innate immunity is essential for the protection
of organisms, it must be properly regulated because unre-
strained DC activation can lead to chronic inflammation
and a response against self (Marshak-Rothstein, 2006).
The sustained stimulation of DC maturation generated
by elevated levels of type I IFNs and other proinflamma-
tory cytokines, for example, is associated with the devel-
opment of autoimmune diseases such as systemic lupus
erythematosus (SLE), Sjo¨gren’s syndrome, and psoriasis
(Banchereau and Pascual, 2006). Consistent with a re-
quirement for the eventual inhibition of an inflammatory
response, it is now increasingly evident that TLR activation
in DCs drives, and is modulated by, the production of neg-
ative regulators that feed back upon and inhibit this activa-
tion (Liew et al., 2005). Prominent among such TLR-driven
inhibitors are the SOCS proteins, whose importance to the
maintenance of immune homeostasis is highlighted by
the phenotype of SOCS1-deficient mice, which exhibitInc.
hyperactivation of DCs and develop lupus-like disease
(Hanada et al., 2003). Their importance notwithstanding,
how the induction of negative regulators is integrated
with the TLR-activated inflammation response remains
to be elucidated.
Here, we identify a novel negative regulatory pathway
driven by receptor tyrosine kinases of the Tyro3-TAM fam-
ily (Lai and Lemke, 1991) and establish its role as a pleio-
tropic inhibitor of both TLR- and cytokine-driven immune
responses.We have previously shown that loss of function
of the three TAM receptors, Tyro3, Axl, andMer, results in
profound dysregulation of the immune response (Caraux
et al., 2006; Lemke and Lu, 2003; Lu and Lemke, 2001).
Tyro3/Axl/Mer/ triple mutant mice (TAM TKOs) dis-
play massive splenomegaly and lymphadenopathy, lym-
phocyte infiltration of essentially all tissues, high-circulat-
ing autoantibody titers, and broad spectrum autoimmune
disease (Lu and Lemke, 2001). Even Mer/ single mu-
tants develop appreciable splenomegaly and are hyper-
sensitive to LPS-induced endotoxic shock (Camenisch
et al., 1999). These phenotypes are cell nonautonomous
with respect to lymphocytes and are thought to result
from the loss of TAM signaling in antigen-presenting cells
(Lu and Lemke, 2001; Lemke and Lu, 2003). We now com-
prehensively analyze TAM function in the DC subset of
APCs. We describe a previously unrecognized pathway
of TAM-mediated negative regulation of both TLR activa-
tion and cytokine production in these cells and demon-
strate that this pathway controls the phased attenuation
of APC activation.
RESULTS
Dendritic Cell Hyperactivation and Expansion
in TAM Triple Knockouts
The phenotypes of TAM TKOs suggested that their auto-
immune syndromes might be due to abnormalities in
APC physiology (Lu and Lemke, 2001). We therefore as-
sessed the status of the DC subset of professional APCs
in TAM TKO spleens. The percentage of splenic CD11c+
cells was markedly elevated in TAM TKOs relative to the
wild-type (WT), as was the absolute number of CD11c+
cells (Figures 1A and 1B). Splenic DCs were also hyperac-
tivated in the triple mutants. CD11c+ DCs in TAM TKOs
expressed higher levels of MHC class I and class II
(Figure 1C) and of BAFF (Figure 1D), which is elevated in
patients with autoimmune disease (Collins et al., 2006).
We previously demonstrated that TAM TKO DCs and
macrophages express super-elevated levels ofMHCclass
II and B7.2 in response to intraperitoneal injection of LPS
(Lu and Lemke, 2001). These and other indices of immune
activation, such as autoantibody titers and splenomegaly,
showagenedosageeffect through theTAMmutant series:
They are more severe in Tyro3/Axl/, Axl/Mer/,
andTyro3/Mer/doublemutants than in any singlemu-
tant and are most severe in TAM triple mutants (Lu and
Lemke, 2001). In agreement with these observations, we
find that splenic DCs isolated from WT, Axl/, Mer/,Cell 1or TAM TKOmice show progressive hyperresponsiveness
to TLR activation, exhibiting an additive gene dosage
effect that is consistent with the coexpression of TAM
receptors documented in many cell types (Lu et al., 1999;
Prasad et al., 2006). In response to the activation of TLR9
with CpG or of TLR4 with LPS, Axl/, Mer/, and TAM
TKODCs produced elevated levels of IL-6 and TNF-a rela-
tive to WT DCs, with the levels produced by TKO DCs
being highest (Figures 1E and 1F). Activation of TLR3
with poly I:C yielded comparable results (data not shown).
The increase in cytokine production in mutant DCs cannot
be attributed to amutation-induced shift in subpopulations
of DCs because the percentage of conventional and plas-
macytoid CD11c+ cells was comparable between WT and
mutant splenic DC cultures (data not shown).
TAM Receptor Activation Inhibits TLR-Induced
Cytokine Production
Given these results, we asked whether treatment with
TAM receptor agonists might inhibit TLR-driven cytokine
production in WT DCs. We studied both splenic CD11c+
DCs and DCs differentiated from mouse bone marrow
(BM) in the presence of FLT-3 ligand. In both populations,
we find that the major TAM receptors expressed are Axl
and Mer (Figure 1G), with no detectable Tyro3. TAM re-
ceptors are activated by the binding of two closely related,
soluble ligands—Gas6 and Protein (ProS) (Prasad et al.,
2006; Stitt et al., 1995). Overnight (15 hr) coincubation of
Gas6 with CpG substantially inhibited TLR9-induced pro-
duction of type I IFNs, IL-6, and TNF in wild-type DCs
(Figure 1H). TAM inhibition was not limited to TLR9: A
comparable Gas6-mediated inhibition of TLR4(LPS)-
induced TNF and IL-6 production (Figure 1I), and of
TLR3(poly I:C)-induced type I IFN, was also observed
(Figure 1J). DC viability was unaffected by Gas6 treatment
(data not shown), and the inhibitory effect of Gas6 was
seen in both BM-DCs and splenic DCs. Finally, ProS
was equally effective at inhibiting TLR-induced cytokine
production in WT DCs (Figure S1A in the Supplemental
Data available with this article online). Thus, TAM activa-
tion broadly inhibits the production of cytokines induced
by the ligation of TLR3, TLR4, and TLR9.
TAM Inhibition Acts on Conserved Components
of TLR Signaling Pathways and Requires New
Gene Expression
TLR activation leads to the engagement of multiple down-
stream signaling cascades. ERK1/2 and p38 MAP kinase,
for example, are well-characterized effectors that are
activated (phosphorylated) by TLR ligation (Dong et al.,
2002). Treatment of DCs with CpG resulted in the phos-
phorylation of both p38 (Figure 2A) and ERK1/2 (Figure 2B)
within 60 min, and we found that these activating phos-
phorylations were completely blocked by 2 hr prior incu-
bation with Gas6 (Figures 2A and 2B). TLR signaling also
leads to the degradation of the NF-kB inhibitors IkBa/b,
and the consequent activation of NF-kB-driven transcrip-
tion (Hoffmann and Baltimore, 2006). Treatment of31, 1124–1136, December 14, 2007 ª2007 Elsevier Inc. 1125
Figure 1. Hyperactivation of DCs in TAM Mutant Mice and TAM Inhibition of TLR-Induced Cytokine Production
(A) Representative FACS analyses of CD11c+ splenocytes from WT and TAM TKO mice. Cells negative for NK1.1, CD19, and CD3 were gated for
CD11c. Numbers in boxed areas are percentage of cells in the gate.
(B) The experiment shown in (A) was independently repeated, with the percentage (left) and total number (right) of CD11c+ cells in the spleens of WT
and TAM TKO mice represented as bar graphs. Error bars represent mean ± SD (n = 6 mice per group, p < 0.01).
(C) FACS histograms of MHC-I and MHC-II expression on CD11c+ cells from WT (black) and TAM TKO (red) spleens. Results are representative
of three independent experiments.
(D) Relative levels of BAFF mRNA in TAM TKO splenic CD11c+ cells, normalized to WT, as determined by Q-PCR. Error bars represent mean ± SD
(n = 3, p < 0.01).
(E and F) IL-6 and TNF-a levels produced by WT, Axl/, Mer/, and TAM TKO splenic CD11c+ cells after 15 hr stimulation with the indicated TLR
agonist, as determined by ELISA. Results are representative of three independent experiments.
(G) Immunoblots of BM-DC cell lysates probed with Axl and tubulin (top blots) and Mer and actin (bottom blots) antibodies. Identical results were
obtained with lysates prepared from splenic CD11c+ cells.
(H–J) Relative production of the indicated cytokines after 15 hr stimulation of DCs with 10 nM CpG (H), 10 ng/ml LPS (I) or 10 mg/ml Poly I:C (J), either
alone () or concomitantly with (+) 50 nM Gas6. Results were normalized to the production of the corresponding cytokine in the presence of the TLR
ligand alone. Error bars represent mean ± SD (nR 3 per group, p < 0.01).BM-DCs with CpG led to the degradation of both IkBa and
IkBb beginning at 60 min (Figure 2C), and this degradation
was again completely blocked by prior incubation with
Gas6 (Figure 2C). The other TAM ligand, ProS, displayed
similar effects in inhibiting CpG-induced phosphorylation
of p38 and ERK1/2 (Figure S1B) and CpG-induced degra-
dation of IkBa and IkBb (Figures S1C andS1D). Thus, TAM
activation inhibits conserved components of TLR signal-
ing pathways in DCs.
TAM inhibition of these pathways operates downstream
of multiple TLRs. Activation of the MAP kinase and NF-kB1126 Cell 131, 1124–1136, December 14, 2007 ª2007 Elseviepathways by TLR3 was also inhibited by Gas6 (Figures
S2A and S2B). Similarly, activation of p38 and ERK1/2,
as a consequence of TLR4 ligation, was also inhibited by
prior incubation with Gas6 (Figures S2C and S2D). The
TLR9 and TLR3 pathways are classical examples
of MyD88-dependent and MyD88-independent (TRIF-
dependent) pathways, respectively, and both of these
pathways are inhibited by TAM signaling.
Importantly, TAM inhibition of TLR signaling requires new
gene expression and protein synthesis. In the presence of
either the protein synthesis inhibitor cycloheximide or ther Inc.
Figure 2. TAM Receptor Activation Inhibits Conserved Components of the TLR9 Signaling Pathway
Cell lysates were prepared from BM-DCs activated for the indicated time with CpG alone, or after a 2 hr preincubation with 50 nM Gas6.
(A) Immunoblots probed for phospho-p38 Thr180/Tyr182 (top) and total p38 (bottom).
(B) Immunoblots probed for phospho-ERK 1/2 Thr183/Tyr185 (top) and total ERK 1/2 (bottom).
(C–E) Quantitative Li-Cor Odyssey immunoblots probed for IkBa, IkBb, and tubulin (left), and measured IkBa:tubulin and IkBb:tubulin signal ratios
(right, mean ± SD; n = 3). DCs were activated as described (C). In addition, DCs were pretreated with 10 mg/ml cycloheximide (D), or with 1 mg/ml
actinomycin D (E), for 30 min prior to the addition of Gas6.RNA synthesis inhibitor actinomycin D, both the kinetics
and magnitude of CpG-induced degradation of IkBa and
IkBb were the same, irrespective of the presence or ab-
sence of Gas6 (Figures 2D and 2E). These observations
indicate that activation of the TAM receptors results in
the induction of one or more genes and proteins that neg-
atively regulate TLR signaling.
TAM Receptor Activation Induces SOCS1 and
SOCS3 and Inhibits Ubiquitylation of the TLR
Receptor-Proximal Elements TRAF3/6
Several TLR inhibitors have been described (Liew et al.,
2005). We took a candidate-based approach to test
whether any of these negative regulators might be in-
duced in response to TAM activation. The suppressor of
cytokine signaling (SOCS) proteins, for example, function
broadly in immune cells as inhibitors of both TLR and
cytokine-receptor signaling (Frobose et al., 2006; MansellCellet al., 2006; Wormald and Hilton, 2007; Yoshimura et al.,
2005) and are induced in DCs by the cytokine-receptor
activation that follows TLR ligation. Of particular interest
is SOCS1 because SOCS1 knockout mice that are recon-
stituted for SOCS1 expression in lymphocytes display
many of the same autoimmune phenotypes as the TAM
TKOs (Hanada et al., 2003). We found that both SOCS1
and SOCS3 are induced in BM-DCs in response to TAM
activation (Figure 3A). SOCS3 mRNA expression in-
creased by 30 min after the addition of Gas6, and peak
expression (10-fold) occurred at approximately 90 min.
SOCS1 mRNA expression increased by 10-fold at
120 min. We also examined mRNAs encoding six other
negative regulators of TLR signaling—IRAK-M, SHIP,
ATF-3, IRF-4, Triad3A, and Tollip (Liew et al., 2005; Ne-
gishi et al., 2005; Gilchrist et al., 2006). In contrast to
SOCS1, none of these mRNAs displayed significant in-
duction after TAM activation (Figure 3B). Thus, the131, 1124–1136, December 14, 2007 ª2007 Elsevier Inc. 1127
SOCS1 and SOCS3 genes are specifically induced down-
stream of TAM signaling.
The TNF-receptor-associated factors (TRAFs) aremajor
early signal transducers for both the TNF receptor and the
IL-1R/TLR superfamilies, and two of these proteins—
TRAF3 and TRAF6—are critical for TLR signaling; they ac-
tivate the MAPK and NF-kB signaling pathways in DCs
(Hacker et al., 2006). TRAF6 functions as an ubiquitin
ligase and is itself activated by ubiquitylation, whereas
TRAF3 shares extensive homology with TRAF6. We read-
ily detected polyubiquitylated forms of both TRAF6 and
TRAF3 in BM-DCs within 30 min after TLR4 activation
with LPS and found that this polyubiquitylation is potently
inhibited by 2 hr prior incubation with Gas6 (Figures 3C
and 3D). Thus, TAM-mediated inhibition operates at a re-
ceptor-proximal point in TLR cascades, thereby eliciting
a pleiotropic downregulation of TLR-activated signaling.
The IFNAR/STAT1 Signaling Cassette Is an
Essential Component of TAM-Mediated Inhibition
What transcription factors might mediate the induction of
SOCS1/3 and other TAM-dependent genes? We have
obtained evidence that STAT1 is one such regulator.
STAT proteins are classically activated by tyrosine phos-
phorylation, frequently by JAK family tyrosine kinases, in
Figure 3. TAM Activation Induces SOCS1/3 and Inhibits
TLR4-Induced Ubiquitylation of TRAF3/6
(A) BM-DCs were activated for the indicated time with 50 nMGas6 and
then assayed for expression of SOCS1 and SOCS3mRNA by Q-PCR.
SOCS1/3 mRNA levels relative to b-actin were normalized to those of
nonstimulated cells. Error bars represent mean ± SD (n = 4 for SOCS1;
n = 3 for SOCS3).
(B) Cells were treated as in (A) and then assayed for expression of the
indicated inhibitor mRNAs by Q-PCR. Error bars represent mean ± SD
(n = 2).
(C) BM-DCs were incubated for 0 or 30 min with 1 mg/ml LPS alone, or
for 30 min with LPS after a 2 hr preincubation with 50nM Gas6. TRAF6
was immunoprecipitated and analyzed by immunoblotting with ubiqui-
tin (top blot) and TRAF6 (bottom blot) antibodies.
(D) Cells were treated as in (C). TRAF3 was immunoprecipitated, and
its ubiquitylation was assessed by immunoblotting with ubiquitin (top
blot) and TRAF3 (bottom blot) antibodies.1128 Cell 131, 1124–1136, December 14, 2007 ª2007 Elsevierresponse to interferons, interleukins, and other extracellu-
lar signals (Levy and Darnell, 2002). This activation results
in the translocation of phosphorylated STAT dimers from
the cytoplasm to the nucleus, in which they drive the
expression of downstream genes. Phosphorylation of
STAT1 at Y701 is required for STAT1 transcriptional acti-
vation (Levy and Darnell, 2002). By using an antibody
specific for phospho-STAT1 (Y701), we observed that
STAT1 is activated in DCs after incubation with Gas6
(Figure 4A). This activation is inhibited by treatment with
soluble Axl-Fc, which competes with TAMs for Gas6 bind-
ing (Figure 4B) and is not seen in TAM triple mutant DCs
(Figure S3A). These observations are consistent with a de-
cade-old report that a constitutively active form of chicken
Mer (v-Eyk) stimulates tyrosine phosphorylation of STAT1
and that this stimulation requires Eyk kinase activity (Zong
et al., 1996). We also assayed the activation of two other
members of the STAT family—STAT2 and STAT3—in
response to Gas6 and did not detect TAM-mediated
phosphorylation of these STATs (Figure S3B).
In order to assess whether STAT1 is required for TAM
inhibition of TLR signaling, we assayed the ability of
Gas6 to upregulate SOCS1 and SOCS3 expression in
BM-DCsprepared fromSTAT1 knockouts. Gas6 induction
of SOCS1mRNA, which is typically10-fold after 120min
in WT DCs, was completely abolished in STAT1/ DCs
(Figure 4C). Gas6 induction of SOCS3 mRNA, although
not eliminated entirely, was nonetheless substantially re-
duced (Figure 4D). Basal levels of protein and mRNA for
Axl, a critical TAM component in DCs, were comparable
between WT and STAT1/ DCs (see Figures 5C and
5D). We also attempted to assay the ability of Gas6 to
inhibit the expression of a panel of cytokines in response
to TLR activation in the presence or absence of endoge-
nous STAT1. However, most of these cytokines—includ-
ing IFNa and IL-12—are themselves almost entirely
dependent upon STAT1 for their TLR-induced activation
because they require a STAT1-dependent, cytokine-re-
ceptor-mediated amplification step (Honda et al., 2006).
Thus, we were unable to detect any secretion of IFNa or
IL-12 in STAT1/ DCs in response to LPS or CpG (data
not shown). However, both LPS- and CpG-triggered
expression of IL-6, albeit reduced, were still readily
detected in STAT1/DCs (Figures 4E and 4F). In contrast
to WT DCs, the expression of IL-6 triggered by LPS
(Figure 4E) or CpG (Figure 4F) was not inhibited by Gas6
in STAT1/ cells. Indeed, cytokine production was often
slightly elevated by Gas6 treatment in STAT1/DCs (Fig-
ures 4E and 4F). Together, these results demonstrate that
STAT1 is essential for both TAM induction of SOCS genes
and inhibition of TLR-driven cytokine production. Not
unexpectedly, we found that STAT1-dependent SOCS ex-
pression is also critical for the inhibition of receptor-proxi-
mal steps of TLRcascades. TAM inhibition of LPS-induced
TRAF6 ubiquitylation and IkBa degradation were both lost
in STAT1/ BM-DCs (Figures S3C and S3D).
As noted above, STAT proteins, including STAT1, are
typically associated with signal transduction cascadesInc.
Figure 4. IFNAR/STAT1 Signaling Is Acti-
vated by TAM Receptor Activation and Is
Required for TAM Induction of SOCS
Genes and Inhibition of Cytokine Pro-
duction
(A) Splenic DCs were incubated for the indi-
cated time with 50 nM Gas6, and cell lysates
were analyzed by immunoblotting for phos-
pho-STAT1 Tyr 701 (top blot) and total STAT1
(bottom blot).
(B) BM-DCs were incubated with 50 nM Gas6
alone or after a preincubation of 10 min with
100 nM Axl-FC. Cell lysates were analyzed as
in (A).
(C and D) BM-DCs from WT (black bars) and
STAT1/ (gray bars) mice were incubated for
the indicated time with 50 nM Gas6, and ex-
pression of SOCS1 (C) and SOCS3 (D) mRNAs
was determined by Q-PCR. mRNA levels rel-
ative to b-actin expression were normalized
to nonstimulated cells. Error bars represent
mean ± SD, n = 2.
(E and F) BM-DCs from WT (black points) and
STAT1/ (gray points) mice were stimulated
with 10 ng/ml LPS (E) or 3 nM CpG (F), either
alone () or concomitantly with (+) 50 nM
Gas6. After 15 hr, levels of secreted IL-6
were determined by ELISA (detection limit
4 pg/ml). Note the expansion of the y axis
for the STAT1/ measurements in (E) and (F).
(G) Cell lysates of BM-DCs from either WT (left)
or Ifnar1/ (right) mice, either untreated () or
treated with (+) 50 nM Gas6 for 60 min, were
analyzed by immunoblotting for activated
phospho-STAT1 (top blots) and total STAT1
(bottom blots).
(H) BM-DCs fromWT (black bars) and Ifnar1/
(gray bars) mice were incubated for the indi-
cated time with 50nM Gas6, and expression
of SOCS1 mRNA was determined by Q-PCR.
mRNA levels relative to b-actin expression
were normalized to nonstimulated cells. Error
bars represent mean ± SD, n = 2.
(I) BM-DCs fromWT (black points) and Ifnar1/
(gray points)micewere stimulatedwith 10 ng/ml
LPS, either alone () or concomitantly with (+)
50 nM Gas6. After 15 hr, levels of secreted
IL-6 were determined by ELISA.
(J) BM-DC cell lysates, either untreated () or
treated for 20minwith 50 nMGas6 (+), were immunoprecipitatedwith antibodies to the R1 (left blots) or R2 (right blots) chain of the type I IFN receptor.
Immunoprecipitates were resolved on SDS gels, which were then immunoblotted with antibodies against Axl (top blots), the IFN receptor R1 chain
(middle-left blot), the IFN receptor R2 chain (middle-right blot), or STAT1 (bottom blots). An equivalent association of Axl with the R1 chain of the IFN
receptor was also seen in Axl’s IPs that were immunoblotted with anti-IFNAR1 (data not shown).downstream of cytokine receptors, most notably the type I
IFN receptor. We therefore asked whether the STAT1-de-
pendent, TAM-mediated inhibition of inflammation docu-
mented above might reflect a broader requirement for
signaling by the type I IFN receptor (IFNAR). We prepared
BM-DCs from Ifnar1 knockouts, which are mutant for the
R1 subunit of the a/b receptor and lack all type I signaling,
and assayed these mutant cells for STAT1 tyrosine phos-
phorylation in response to Gas6 application. In contrast
toWT BM-DCs, we found that Ifnar1/ cells were incapa-
ble of activating STAT1 upon TAM receptor activationCel(Figure 4G). This effect was not due to a lack of TAM
receptor expression in Ifnar1/ DCs because Axl and
Mer were still detected in these cells, and it was also not
due to any Gas6 induction of IFN production in WT cells
because this was not observed (data not shown). In keep-
ing with the loss of Gas6-induced STAT1 phosphorylation,
we also found that Gas6 was unable to upregulate SOCS1
expression (Figure 4H), and unable to inhibit LPS-induced
production of IL-6, in Ifnar1/ DCs (Figure 4I). Consistent
with all of these effects, we found that the R1 chain of
the type I IFN receptor and Axl physically associate inl 131, 1124–1136, December 14, 2007 ª2007 Elsevier Inc. 1129
BM-DCs, in a TAM-ligand-dependent fashion, and can be
reciprocally coimmunoprecipitated (Figure 4J). These re-
sults indicate that TAM inhibition of inflammation in DCs
is dependent on the presence of the type I IFN receptor.
Thus, TAM receptors employ the IFNAR/STAT1 signaling
cassette, which is initially used to trigger inflammation,
to subsequently inhibit inflammation.
Regulation of TAM Receptor Signaling Is Itself
a Feature of the Innate Immune Response
The above results indicate that TAM signaling broadly
inhibits inflammatory responses driven by TLR and cyto-
kine-receptor activation. This suggests that the TAM sys-
tem should not be fully engaged at the beginning of the
innate immune response, and further, that some feature
of the system, e.g., TAM receptor or ligand expression,
should be upregulated subsequent to TLR and cytokine-
receptor activation.
Figure 5. TLR Induction of TAM Signaling Is Activated in an
IFNAR/STAT1-Dependent Fashion
(A) BM-DCs were incubated for the indicated time with 30 mg/ml Poly
I:C or 100 ng/ml LPS, and expression of AxlmRNA was determined by
Q-PCR. mRNA levels relative to b-actin expression were normalized to
nonstimulated cells. Error bars represent mean ± SD (n = 2).
(B) Representative FACS histograms of Axl expression on nonstimu-
lated WT CD11c+ cells (gray lines) or CD11c+ cells stimulated with
30 mg/ml Poly I:C for 12 hr (black lines). Dotted gray histogram repre-
sents TAM TKO control.
(C–E) BM-DCs—prepared from WT, STAT1/, and Ifnar1/ mice—
were incubated for the indicated hours with 30 mg/ml Poly I:C (C and
E) or 3000 U/ml IFNa (D), and cell lysates were analyzed by immuno-
blotting for Axl (top blots) and tubulin expression (bottom blots).
Wild-type controls are from strain 129 mice for (C) and (D) and from
C57Bl/6 for (E).1130 Cell 131, 1124–1136, December 14, 2007 ª2007 ElsevieWe therefore assayed the expression of Axl, Mer, Gas6,
andProSmRNAandprotein inBM-DCs, in response to the
activation of various TLRs. We observed that Axl mRNA
and protein levels were markedly elevated upon treatment
withmultiple TLRagonists (Figures 5Aand5B). In contrast,
we did not detect any significant change in Mer, Gas6, or
ProS mRNA expression in BM-DCs subsequent to TLR
activation (data not shown). Although the addition of exog-
enous TAM ligands consistently stimulates TAM signaling
in our DC cultures, we nonetheless detected both endog-
enousGas6 and ProSmRNA in these cultures, suggesting
that in DCs, as inmany other cell types, TAM signaling is at
least partially autocrine-paracrine (Lu et al., 1999; Lu and
Lemke, 2001; Prasad et al., 2006).
This finding of TLR-driven Axl upregulation is of partic-
ular interest, given our recent collaborative demonstration
that type I IFNs, which are themselves induced down-
stream of TLR activation and can in certain settings also
be immunosuppressive, also markedly upregulate Axl
expression inmacrophages (Sharif et al., 2006). IFN induc-
tion of Axl is required for IFN suppression of TLR-driven
TNF production because no suppression is observed in
Axl/ macrophages (Sharif et al., 2006). In light of these
findings and the results presented in Figures 5A and 5B,
we asked whether Axl upregulation in response to either
TLR ligation or type I IFN treatment is itself dependent
on the IFNAR/STAT1 signaling cassette. We find that
this is indeed the case, for both forms of DC stimulation.
We stimulated BM-DCs from WT, STAT1/, or Ifnar1/
mice for varying periods of time with either poly I:C or
IFNa and then assayed for Axl expression by immunoblot-
ting. Both poly I:C and IFNa induced substantial upregula-
tion of Axl in WT DCs (Figures 5C–5E). In marked contrast,
Axl induction after treatment with either poly I:C or IFNa
was lost in STAT1/ DCs (Figures 5C and 5D). At the
same time, poly I:C induction of Axl was also lost in
Ifnar1/ DCs (Figure 5E). Together, these results argue
that the Axl upregulation we detect in response to TLR
ligation is due to the induction of type I IFNs after TLR ac-
tivation and that it is these cytokines that then induce Axl.
Thus, proinflammatory activation of the innate immune re-
sponse results in the downstream activation of anti-
inflammatory TAM signaling.
TLR, IFNAR/STAT1, and TAM Signaling Are
Integrated into a Cyclic Innate Immune Response
Given both these results and our observation that TAM
activation directly induces SOCS genes (Figure 3A), we
asked whether the well-described induction of these
genes in response to type I IFNs and other cytokines (Wor-
mald and Hilton, 2007; Yoshimura et al., 2005) might re-
quire TAM signaling. We assayed the ability of IFNa to el-
evate expression of SOCS1 mRNA in either WT or TAM
TKO splenic DCs. Although 300 U/ml IFNa stimulated
robust induction of SOCS1mRNA after 2 hr and sustained
upregulation up to 6 hr in WT DCs, SOCS1 induction was
significantly blunted in TAM TKO cells (Figure 6A). This
effect was evident at 2 hr after the addition of IFNa butr Inc.
was even more pronounced at later time points, consis-
tent with IFNa upregulation of Axl in WT DCs (Figure 5D)
(Sharif et al., 2006). Integrated over the 6 hr course of
the experiments (Figure 6A), IFN-treated TAM TKO DCs
expressed only 24% of the SOCS1 mRNA expressed
by IFN-treated WT DCs. We also assayed mRNA levels
for IRF-7 and IFI-204, two positive effectors of IFN signal-
ing, in the same RNA samples. In contrast to the SOCS1
inhibitor, IFNa-induced mRNA levels for these stimulators
of IFN signaling were indistinguishable between WT and
TAM TKO DCs (Figures 6B and 6C).
These observations led us to examine the potential
interaction of IFN receptor and TAM receptor signaling in
greater detail. Consistent with the above results and in ob-
vious contrast to the SOCS inhibitors, we found that the
IRF-7 and IFI-204 positive effectors were not induced in
BM-DCs by direct TAM activation (addition of Gas6 alone)
(Figure 6D). More tellingly, we found that addition of Gas6
and IFNa in combination resulted in higher induced levels
of SOCS1mRNA than those seen with either ligand alone
(Figure 6D, left bars), whereas the expression of both IRF-7
and IFI-204 mRNA, measured in the same experiment,
was markedly lower in BM-DCs treated with Gas6 and
IFNa in combination than in cells treated with IFNa alone
(Figure 6D, middle and right bars). Thus, TAMs and IFN
receptors interact positively to induce the expression of
cytokine signaling inhibitors but interact negatively to
inhibit the expression of cytokine signaling stimulators.
Taken together, the results of Figures 4, 5, and 6 indicate
that TAM signaling is induced—in a sequential, IFNAR/
Figure 6. Integration of TAM and IFN Receptor Signaling
(A) Splenic CD11c+ cells from WT (white bars) and TAM TKO (black
bars) mice were incubated for the indicated time with 300 U/ml IFNa,
and expression of SOCS1 mRNA was determined by Q-PCR. mRNA
levels relative to b-actin were normalized to nonstimulated cells.
(B and C) The same mRNA samples used in (A) were analyzed for ex-
pression of IRF-7 mRNA (B) and IFI-204 mRNA (C) by Q-PCR. mRNA
levels relative to b-actin were normalized to nonstimulated cells.
(D) RNA samples prepared fromBM-DCs incubated for 2 hr with 50 nM
Gas6 (white bars), 30 U/ml IFNa (gray bars), or Gas6 plus IFNa together
(black bars) were analyzed for expression SOCS1 mRNA (left), IRF-7
mRNA (middle), and IFI-204 mRNA (right) by Q-PCR. mRNA levels
relative to b-actin were normalized to nonstimulated cells. Error bars
for all panels represent mean ± SD (n = 4).Cell 1STAT1-dependent fashion—subsequent to first TLR
and then cytokine-receptor activation. Remarkably, this
induced TAM signaling, rather than cytokine signaling, ac-
counts for most of the SOCS protein elevation that is seen
as a consequence of cytokine-receptor activation. This
SOCS elevation, which appears to be a major component
of TAM-mediated inhibition, depends on the ability of the
TAM receptors to hijack the proinflammatory IFNAR/
STAT1 signaling cassette to inhibit inflammation. Most im-
portantly, our results suggest that the TAMpathway serves
as the terminal component of a tripartite inflammatory cy-
cle, composed of initial inflammation, subsequent cyto-
kine amplification, and TAM-mediated inhibition (Figure 7).
DISCUSSION
Our results demonstrate that TAM activation in DCs
inhibits the secretion of a panoply of TLR- and cytokine-
receptor-driven cytokines. We propose that both TAM
engagement and action are integrated as components of
an inflammation cycle that is initiated by TLR ligation
(Figure 7B). The output of the first stage of this cycle (green
pathways in Figures 7A and 7B) is an initial burst of cyto-
kines. This burst is then amplified via a feed-forward
loop through cytokine receptors (blue pathways in Figures
7A and 7B), a process that is almost entirely dependent on
STAT proteins, notably STAT1 (Honda et al., 2006). In
addition to elevated cytokine levels, our data indicate
that a key output from this second stage of inflammation
is the induction of Axl (Figure 5D; Sharif et al., 2006). Our
data further indicate that Axl induction by both IFNAR/
STAT1 signaling (Figures 5D and 5E) and TLR ligation
(Figure 5C) occurs predominantly through TLR activation
of this feed-forward cytokine pathway. The final stage of
the inflammatory cycle we propose (red pathways in Fig-
ures 7A and 7B) involves the engagement of TAM signal-
ing, the transcription of SOCS genes, and the pleiotropic
inhibition of both cytokine receptor and TLR signaling
pathways. In concert with TAM activation, this final inhib-
itory phase again employs the IFNAR/STAT1 signaling
cassette (Figures 4C–4J; Figures S3C and S3D). In vivo,
many or most migratory DC subsets will transit this cycle
only once, prior to their apoptotic elimination in the lymph
nodes. However, macrophages, in which TAM signaling
also operates (Lu and Lemke, 2001), might transit the
cycle reiteratively. As discussed below, the inflammation
cycle schematized in Figure 7 might account for several
incompletely understood response phenomena in APCs
and might also have implications for the understanding
of human immune system disorders.
Control Points for TAM Inhibition
TAM inhibition is seen at multiple points in TLR signaling
cascades. TLR3-, TLR4-, and TLR9-induced activation
of MAP kinases and NF-kB are all markedly reduced
upon TAM engagement (Figure 2; Figures S1 and S2),
but so is the TLR-induced ubiquitylation and activation
of TRAF6 (Figure 3C). TRAF3 is also required for31, 1124–1136, December 14, 2007 ª2007 Elsevier Inc. 1131
Figure 7. A TAM-Regulated Cycle of Inflammation
(A) Schematic representation of the sequential engagement of TLR (green), cytokine receptor (blue), and TAM receptor (red) signaling pathways
in APCs.
(B) Schematic representation of the inflammatory cycle initiated by TLR ligation (green pathway). Activation of TLRs leads to an initial burst of cyto-
kines. This burst is then amplified in a second stage, via a feed-forward loop through cytokine receptors (blue pathways). At the same time, activation
of cytokine receptors leads to an IFNAR/STAT1-dependent induction of Axl. The final stage of the cycle (red pathways) involves the engagement of
TAM signaling, the transcription of SOCS genes, and the pleiotropic inhibition of both cytokine receptor and TLR signaling pathways. This final TAM-
driven inhibitory phase is also dependent on the IFNAR/STAT1 signaling cassette, which is physically associated with TAM receptors.a response to TLR3 and TLR4 (Hacker et al., 2006), andwe
found that TRAF3 is also polyubiquitylated upon TLR4
ligation—this had not been demonstrated previously—
and that this ubiquitylation is also inhibited by TAM activa-
tion (Figure 3D). At the same time, TAM activation leads to
the IFNAR/STAT1-dependent appearance of SOCS1 and
SOCS3 (Figures 4C, 4D, and 4H). SOCS1 has recently
been demonstrated to promote the degradation of the
TLR4 adaptor protein MAL (Mansell et al., 2006), and
SOCS3 overexpression has also been reported to inhibit
TRAF6 ubiquitylation (Frobose et al., 2006). Thus, TAM-
induced SOCS1 and SOCS3 are bona fide negative regu-
lators of TLR signaling.
TAM inhibition is also exerted at the second stage of
inflammation. This later activity reflects the well-described
role that SOCS1 and SOCS3 play in the inhibition of the
JAK-STAT pathway and the attenuation of cytokine-
receptor signaling (red inhibition in Figure 7; Wormald
and Hilton, 2007; Yoshimura et al., 2005). TAM activation
therefore inhibits both TLR-proximal signaling events
(TRAF3/6 ubiquitylation, MAP kinase and NF-kB signaling)
and the feed-forward amplification of cytokine production
through cytokine-receptor cascades.
STAT1 Redux
A very large body of literature demonstrates that STAT1
plays a pivotal role as a transducer of multiple cytokine
receptors, such as the interferon (a/b/g) and interleukin1132 Cell 131, 1124–1136, December 14, 2007 ª2007 Elsevierreceptors, in DCs and other APCs (Levy and Darnell,
2002). After cytokine-receptor and associated JAK kinase
activation, STAT1 becomes phosphorylated and translo-
cates to the nucleus, in which it drives the transcription
of many proinflammatory target genes. Among the most
prominent of these targets are cytokine genes themselves
(Honda et al., 2006; blue pathways in Figures 7A and 7B).
Our data demonstrate that an additional key target of
IFNAR/STAT1 signaling during this stage is the Axl gene
(Figures 5C–5E). At the same time that the IFN cascade
is using STAT1 to amplify the cytokine burst produced at
the end of the TLR-driven first stage of inflammation,
this cascade is also using the same transcription factor
to elevate Axl levels. That is, the seeds of the pathway
that will eventually inhibit cytokine production are being
sown at the same time that cytokine levels are being
amplified, and STAT1 is used for both of these events.
However, this is not the end for STAT1 in inflammation.
Both our data (Figures 4A and 4B) and those of Zong et al.
(1996) demonstrate that STAT1 is also specifically acti-
vated as a consequence of TAM receptor activation. Sig-
nificantly, we demonstrate that STAT1, in conjunction with
the type I IFN receptor, is actually required for TAM induc-
tion of SOCS1 and SOCS3 (Figures 4C, 4D, and 4H). More
significant still is the observation that TAM-mediated up-
regulation of SOCS1 appears to account for the majority
of the upregulation of this protein previously documented
in response to type I IFN (Wormald and Hilton, 2007).Inc.
These earlier observations havebeenattributed to adirect,
negative-feedback loop in which IFN and other cytokine
receptors are inhibited by the SOCS proteins that are
induced by the STAT1 that these receptors activate.
Instead, they appear to reflect a significant indirect effect
of IFNa: This cytokine induces Axl, and it is TAM receptors
that then induce SOCS. The TAMs use the IFN receptor-
STAT1 signaling cassette to do this and thus hijack a pro-
inflammatory pathway to inhibit inflammation. Our data
(Figure 4J) suggest that this is achieved by binding of
the TAMs to the IFN receptor’s R1 subunit, which associ-
ates with the R2 subunit, whose cytoplasmic domain
binds STAT1.
Taken together, these results are consistent with
a TAM-mediated subversion of STAT1—from an immune
activator that drives inflammation, the ‘‘blue STAT1’’ in
Figure 7A—to an immune suppressor that drives ex-
pression of the SOCS inhibitors, the ‘‘red STAT1’’ in
Figure 7A. What is different about the anti-inflammatory
(e.g., SOCS-activating) STAT1 downstream of TAM + cy-
tokine-receptor engagement versus the proinflammatory
(e.g., IRF-7-activating) STAT1 downstream of cytokine-
receptor engagement alone? It is possible that alternative
posttranslational modifications of the protein, or alterna-
tive recruitment of cofactors such as Twist (Sharif et al.,
2006), account for this ‘‘blue STAT/red STAT’’ dichotomy.
It is important to note that the demonstration that the TAM
system and type I IFN receptors interact, both physiolog-
ically (Figures 6A–6D) and physically (Figure 4J), is paral-
leled by studies from our group and others that document
an equivalent physiological and physical interaction
between Axl and another cytokine receptor—the IL-15
receptor (Caraux et al., 2006; Budagian et al., 2005).
Activation of first a cytokine receptor alone, and then sub-
sequently a TAM + cytokine-receptor complex, might
have very different consequences for both STAT1 modifi-
cation and the induction of STAT1 transcription-factor
partners.
Physiological Implications
of the Inflammation Cycle
In macrophages, which might transit the inflammation
cycle repeatedly, components of the TAM pathway that
are upregulated during the cycle (e.g., Axl) must turn
over with a half-life that allows responding cells to return
to baseline (gray cell in Figure 7B). This turnover should
be integral to the cycle because Axl upregulation is depen-
dent on cytokine production and IFNAR/STAT1 signaling
(Sharif et al., 2006; Figures 5C–5E), which are inhibited
by TAM signaling. TAM deactivation is required if a reitera-
tively cycling APC is to be fully responsive to subsequent
pathogen encounter: If this encounter occurs before the
TAM system has had time to wind down, then the subse-
quent TLR response will be blunted. As such, the cycle
might be relevant to endotoxin tolerance and immunosup-
pression, a phenomenom in which hyporesponsiveness
to TLR engagement is induced by prior TLR activation
(Broad et al., 2006).CellRemoval of the TAM pathway from the inflammation
cycle is predicted to lead to a sustained hyperresponse
to TLR activation, and this is what we observe in the
TAM TKOs. Mouse knockouts have also been reported
for Gas6 (Angelillo-Scherrer et al., 2001), and it will be of
interest to examine circulating levels of inflammatory cyto-
kines in these mutants. The source of the Gas6 and ProS
required for TAM activation in vivo is at present unre-
solved. Both ligands are detectable in our DC cultures,
and so at least a fraction of TAM signaling in DCs might
be autocrine-paracrine. At the same time, the possibility
that TAM ligands could be delivered to DCs by regulatory
T cells [T(regs)] should be considered. The immunosup-
pressive activity that T(regs) exert against DCs is potenti-
ated by IL-4, which has also been found to potentiate se-
cretion of ProS by primary T cells (Smiley et al., 1997).
TAM Signaling in Human Biology and Disease
Autoimmunity in the TAM mutants results from both sus-
tained APC hyperactivation (Lu and Lemke, 2001 and
this paper) and also from the delayed phagocytic clear-
ance of apoptotic cells, a process in which TAM signaling
also plays an important role (Scott et al., 2001; Lemke and
Lu, 2003). The signal transduction events associated with
TAM activation by apoptotic cells appear to be tied to
those we document in this report because pretreatment
of DCs with apoptotic cells has been found to inhibit,
in a Mer-dependent fashion, TLR-induced activation of
NF-kB (Sen et al., 2007). Indeed, the notable severity of
the autoimmunity displayed by the TAM TKOs is thought
to result from this double dose of phenotypes (Lemke
and Lu, 2003). Does TAMdysfunction contribute to human
disease? Several recent observations are consistent with
this possibility. With regard to autoimmunity, low circulat-
ing levels of free Protein S in patients with SLE have been
reported (Brouwer et al., 2004; Meesters et al., 2007).
Because ProS is a TAM ligand, low ProS levels will result
in reduced TAM signaling and consequently, immune hy-
peractivation. At the same time, SLE patients are prone to
thrombotic strokes (Ruiz-Irastorza et al., 2001), and in
addition to its role as a TAM ligand, ProS is also a blood
anticoagulant.
Elevated TAM signaling might also lead to disease. A
recent clinical report, for example, suggests that hyperac-
tive TAM signaling might play a role in sepsis (Borgel et al.,
2006). In this study, circulating Gas6 levels were found to
be consistently elevated in severe sepsis patients, and
Gas6 elevation was correlated with a patient’s clinical
score and with the occurrence of septic shock. Patients
who succumb to sepsis are subject to the immunosup-
pression phenomenon mentioned above, which compro-
mises their ability to eradicate their primary infection and
also predisposes them to nosocomial infections. High
levels of a TAM ligand that inhibits the innate immune
response; i.e., Gas6, would facilitate such an immune
collapse.
Finally, one immediate therapeutic application of our
findings might be in the area of improved adjuvants for131, 1124–1136, December 14, 2007 ª2007 Elsevier Inc. 1133
immunization. The efficacy of many vaccines is compro-
mised both by limited immunogenicity and the require-
ment for repeated immunization. Small molecule inhibitors
that target the TAM kinases—inhibitors of the inhibitors—
are now attractive candidates for vaccine adjuvants.
Conclusions
The TAM signaling network represents a previously un-
known, yet powerful and broadly acting pathway for the
inhibition of inflammation. The sequential induction of
this pathway by, and its integration with, upstream TLR
and cytokine signaling networks together delimit a cycle
of inflammation that governs innate immune system
homeostasis. Understanding the regulatory mechanics
of this cycle will almost certainly have important implica-
tions for intervention in human immune disorders.
EXPERIMENTAL PROCEDURES
Mice
The mutations in the Tyro3/, Axl/, Mer/, and Ifnar1 mice have
been described previously (Lu et al., 1999; Muller et al., 1994).
C57BL/6J and STAT1/mice were purchased from the Jackson lab-
oratory and Taconic, respectively. Micewere notmaintained in a sterile
environment. The Tyro3 mutants are available from Jackson Labs
(stock no. JR7937).
Antibodies
Rabbit anti-mouse Mer and anti-mouse Tyro3 were generated in our
laboratory (Lai et al., 1994; Prasad et al., 2006). All other antibodies
were purchased from commercial suppliers (see Table S1).
Splenic DC Isolation and BM Cultures
Spleens were incubated with collagenase D (1 mg/ml) for 20 min
at 37C. Splenocytes were collected by homogenization through a
100 mm tissue strainer, red blood cells were lysed, and splenic DCs
were isolated with anti-CD11cmagnetic beads. BM cells were isolated
from femurs and tibias and incubated in RPMI complete medium
(+10% fetal-bovine serum) containing 100 ng/ml of Flt3L (Amgen) for
8–10 days. At day 8,90%of the cells are CD11c+, and60%of these
CD11c+ cells display the phenotype of the splenic CD11b+ conven-
tional DC subset, whereas20%display the phenotype of B220+ plas-
macytoid DCs.
DC Activation Assays
Splenic DC or BM-DCs were cultured overnight in serum-free medium
with the indicated concentrations of LPS from S. minnesota R595 Re
(Alexis), CpG-ODN 1668 (Integrated DNA Technologies), or Poly I:C
(InvivoGen) alone or together with murine recombinant Gas6 (R&D
Systems) or murine recombinant ProS (Prasad et al., 2006). Cytokine
production was quantified by ELISA (ebioscience for IL-12, IL-6, and
TNF-a; PBL-biomedical for IFNa) or by luciferase assay with a cell
line containing an ISRE-luciferase reporter construct for type I IFN
(Jiang et al., 2005). Splenic DCs or BM-DCs were cultured in serum-
free medium and treated with murine recombinant Gas6, murine
recombinant ProS, the TLR ligands indicated above, recombinant
mouse IFNa (PBL Biomedical), mouse Axl-FC chimera (R&D), cyclo-
hexamide (Sigma), or actinomycin D (Sigma).
Immunoblots and Immunoprecipitations
DCs were washed in PBS and harvested in sample buffer with 100 mM
DTT. Cell lysates were resolved by electrophoresis, transferred to
a PVDF membrane, blocked in 3% BSA/TBS-Tween-20, and probed
with the indicated antibodies. For fluorescent western blotting, pro-1134 Cell 131, 1124–1136, December 14, 2007 ª2007 Elsevierteins were transferred to an Immobilon-FL PVDF membrane (Millipore)
and incubated with two primary antibodies in 0.1% casein/PBS-
Tween-20. After incubation with fluorescent secondary antibodies,
membraneswere scannedwith theOdyssey imaging system (LI-COR).
For ubiquitylation assays, 5 3 106 BM-DCs per condition were har-
vested in PBS containing 1%SDS and boiled for 5min. PBS containing
1% Triton X-100, 1 mM DTT, 1 mM Na3VO4, 5 mM NaF, and protease
inhibitors (Complete, Roche) was added, and the mixture was soni-
cated. Lysates were precleared for 1 hr by incubation with Immobilized
rProteinA (RepliGen) and incubated overnight with primary antibody at
4C. Immobilized rProteinA was added for the last 2 hr. Immunoprecip-
itates were washed in PBS containing 0.2% NP-40 and 0.5 M LiCl and
resuspended and boiled in sample buffer with 100 mM DTT.
For coimmunoprecipitation assays, DCs were lysed in 10 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM MgCl2, 2 mM EGTA, 6 mM
b-mercaptoethanol, 1% Triton X-100, protease inhibitors (Roche),
and tyrosine phosphatase inhibitors (Sigma).
RNA Extraction, Reverse Transcription, and Real-Time PCR
Analysis
RNA was isolated with the RNeasy mini kit (QIAGEN). Reverse tran-
scription was performed with RT Superscript III (Invitrogen). PCR reac-
tions were performed on an ABI Prism 7700 Sequence Detection
System with SYBRGreen PCR master mix (Applied Biosystems).
Each reaction was normalized against the expression of b-actin or
GAPDH. We performed analyses of dissociation curves with SDS soft-
ware (Applied Biosystems) to control for nonspecific amplification.
Q-PCR primers used in this paper are listed in Table S2.
Flow-Cytometric Analysis
We incubated cells for 15 min with a rat mAb to CD16/32 to block Fc
receptors and then with primary antibodies for 20 min on ice. MAbs
used against murine molecules are listed in Table S1. For Axl staining,
cells were fixed with 10% paraformaldehyde, permeabilized with
Saponin (0.1%), incubated with Axl (M-20) antibody for 30 min, and in-
cubated with anti-goat Cy5 antibody. Fluorescent cells were acquired
with a FacsSort flow cytometer (Becton Dickinson) and analyzed with
FlowJo (Tree Star) software.
Statistical Analysis
Differences between themeans of experimental groups were analyzed
with a two-tailed Student’s t test. Differences with a p value of 0.05 or
less were considered significant.
Supplemental Data
Supplemental Data include three figures and two tables and are avail-
able with this article online at http://www.cell.com/cgi/content/full/
131/6/1124/DC1/.
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